International Stem Cell (QX) Stock Price

-0.10115 (-11.49%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
International Stem Cell Corporation (QX) ISCO OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10115 -11.49% 0.7788 16:00:05
Open Price Low Price High Price Close Price Prev Close
0.90 0.65 0.90 0.7788 0.87995
Bid Price Ask Price Spread News
0.623 0.95 0.327 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
22 7,843 $ 0.800942 $ 6,282 - 0.27 - 1.08
Last Trade Time Type Quantity Stock Price Currency
15:48:33 100 $ 0.7788 USD

International Stem Cell (QX) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.87M 7.54M 2.19M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
4.04k $ - 0.00% - -

more financials information »

International Stem Cell (QX) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ISCO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.95990.95990.650.92766621,829-0.1811-18.87%
1 Month0.4491.080.4010.904478213,9590.329873.45%
3 Months0.481.080.300.647913410,8440.298862.25%
6 Months0.601.080.300.62676036,6580.178829.8%
1 Year0.611.080.270.61030486,0080.168827.67%
3 Years1.501.900.271.025,683-0.7212-48.08%
5 Years3.404.250.271.375,919-2.62-77.09%

International Stem Cell (QX) Description

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.